About Predigen
Predigen is a Healthcare company based in United States founded in 2014 by Christopher Woods, Geoffrey Ling, and Ephraim Tsalik, and was acquired by Biomeme in August 2021. Gene expression signatures are developed for disease diagnostics. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its competitors include Parse Biosciences, RareCyte and RainDance; 3 of its 3 listed competitors have raised funding.
Company details
Predigen was established in 2014 as a spin-out from Duke University in the United States. Host gene expression signatures are developed by the company for prognostic, diagnostic, and therapeutic monitoring applications. A portfolio of signatures has been created for use in viral, bacterial, and fungal infections, sepsis, cardiovascular disease, radiation exposure, autoimmune and inflammatory conditions, and cancer. Operations are centered on biotechnology for medical diagnostics.
- Headquarters United States
- Founders Christopher Woods, Geoffrey Ling, Ephraim Tsalik
- Stage Acquired
- SectorsHealthcare
- Website predigen.com
- Social LinkedIn X
- Acquired by Biomeme (Aug 2021)
Investors in Predigen
Predigen has secured backing from 1 investor. Prominent investors backing the company include Biomeme.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Smartphone-based DNA detection platform is developed for diagnostics. | 2013 | biomeme.com | Philadelphia, United States |
Investor details for Predigen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Predigen
3 people are tracked at Predigen (3 in leadership).
| Name | Role | Group |
|---|---|---|
Christopher Woods | Co-Founder | Leadership |
Geoffrey Ling | Co-Founder | Leadership |
Ephraim Tsalik | Co-Founder | Leadership |
Complete people profiles for Predigen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Predigen
2 dated milestones of Predigen across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Predigen is founded.
- Exit Acquired by Biomeme.
Competitors of Predigen
Predigen has 3 listed competitors in our database, 3 of them funded. They include Parse Biosciences, RareCyte and RainDance.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| parsebiosciences.com | 2018 | Seattle, United States | $100.26M | RNA-sequencing transcriptome kits for health data analysis are developed. | ||
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems |
Detailed competitors of Predigen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Predigen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Predigen
Complete news archive for Predigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Predigen
Predigen was founded in 2014.
Predigen is headquartered in United States.
Predigen was established in 2014 as a spin-out from Duke University in the United States. Host gene expression signatures are developed by the company for prognostic, diagnostic, and therapeutic monitoring applications. A portfolio of signatures has been created for use in viral, bacterial, and fungal infections, sepsis, cardiovascular disease, radiation exposure, autoimmune and inflammatory conditions, and cancer. Operations are centered on biotechnology for medical diagnostics.
Predigen's top competitors include Parse Biosciences, RareCyte and RainDance.
Predigen has 1 investor. Key investors include Biomeme.
Yes. Predigen was acquired by Biomeme in August 2021.